Evidence map›Paper›PMID 2523411›Full record

ArticleThe Journal of clinical investigation1989

Inhibition of human megakaryocytopoiesis in vitro by platelet factor 4 (PF4) and a synthetic COOH-terminal PF4 peptide.

A M Gewirtz, B Calabretta, B Rucinski, S Niewiarowski, W Y Xu

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 1989. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 146 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Heparin-induced thrombocytopenia in the pediatric population: a review of current literature.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2012
    Article
  7. The role of platelet factor 4 in radiation-induced thrombocytopenia.International journal of radiation oncology, biology, physics · 2011
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Megakaryocyte biology and related disorders.The Journal of clinical investigation · 2005
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Effect of thrombin on maturing human megakaryocytes.The American journal of pathology · 1993
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

A M GewirtzDepartment of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania 19140.
B Calabretta
B Rucinski
S Niewiarowski
W Y Xu
Temple University · US

Funding

REGULATION OF MEGAKARYOCYTOPOIESISR01CA036896 · NCI · UNIVERSITY OF PENNSYLVANIA · PI GEWIRTZ, ALAN M · 1987 to 1995
–
ALTERED GROWTH REGULATION IN HUMAN LEUKEMIAR01CA046782 · NCI · THOMAS JEFFERSON UNIVERSITY · PI CALABRETTA, BRUNO · 1988 to 1999
–
REGULATION OF HUMAN MEGAKARYOCYTOPOIESISR23CA036896 · NCI · TEMPLE UNIVERSITY · PI GEWIRTZ, ALAN M · 1985 to 1986
–
NCI NIH HHS CA-01324NCI NIH HHS CA-36896NCI NIH HHS CA-46782
6 · The paper itself

Abstract

We report that highly purified human platelet factor 4 (PF4) inhibits human megakaryocytopoiesis in vitro. At greater than or equal to 25 micrograms/ml, PF4 inhibited megakaryocyte colony formation approximately 80% in unstimulated cultures, and approximately 58% in cultures containing recombinant human IL 3 and granulocyte-macrophage colony-stimulating factor. Because PF4 (25 micrograms/ml) had no effect on either myeloid or erythroid colony formation lineage specificity of this effect was suggested. A synthetic COOH-terminal PF4 peptide of 24, but not 13 residues, also inhibited megakaryocyte colony formation, whereas a synthetic 18-residue beta-thromboglobulin (beta-TG) peptide and native beta-TG had no such effect when assayed at similar concentrations. The mechanism of PF4-mediated inhibition was investigated. First, we enumerated total cell number, and examined cell maturation in control colonies (n = 200) and colonies (n = 100) that arose in PF4-containing cultures. Total cells per colony did not differ dramatically in the two groups (6.1 +/- 3.0 vs. 4.2 +/- 1.6, respectively), but the numbers of mature large cells per colony was significantly decreased in the presence of PF4 when compared with controls (1.6 +/- 1.5 vs. 3.9 +/- 2.3; P less than 0.001). Second, by using the human leukemia cell line HEL as a model for primitive megakaryocytic cells, we studied the effect of PF4 on cell doubling time, on the expression of both growth-regulated (H3, p53, c-myc,and c-myb), and non-growth-regulated (beta 2-microglobulin) genes. At high concentrations of native PF4 (50 micrograms/ml), no effect on cell doubling time, or H3 or p53 expression was discerned. In contrast, c-myc and c-myb were both upregulated. These results suggested the PF4 inhibited colony formation by impeding cell maturation, as opposed to cell proliferation, perhaps by inducing expression of c-myc and c-myb. The ability of PF4 to inhibit a normal cell maturation function was then tested. Megakaryocytes were incubated in synthetic PF4, or beta-TG peptides for 18 h and effect on Factor V steady-state mRNA levels was determined in 600 individual cells by in situ hybridization. beta-TG peptide had no effect on FV mRNA levels, whereas a approximately 60% decrease in expression of Factor V mRNA was found in megakaryocytes exposed to greater than or equal 100 ng/ml synthetic COOH-terminal PF4 peptide. Accordingly, PF4 modulates megakaryocyte maturation in vitro, and may function as a negative autocrine regulator of human megakaryocytopoiesis.

Indexed as

Amino Acid Sequencebeta-ThromboglobulinCytoplasmic GranulesGrowth InhibitorsHematopoiesisHematopoietic Stem CellsHumansMegakaryocytesPeptide FragmentsPlatelet Factor 4Protein Conformationbeta-ThromboglobulinGrowth InhibitorsPeptide FragmentsPlatelet Factor 4

Identifiers

PMID2523411
PMCPMC303850
OpenAlexW2145699974

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.